CNS Disorders  >>  Isentress (raltegravir)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Isentress (raltegravir) / Merck (MSD)
NCT01529749 / 2011-002071-42: Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated

Completed
4
48
Europe
EFV/FTC/TDF + Losartan, EFV/FTC/TDF, FTC/TDF + MK-0518, FTC/TDF+MK-0518+Losartan
Felipe Garcia
HIV-1 Infection
03/12
02/16
HANDral, NCT01448486: A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV

Terminated
4
6
RoW
Raltegravir, Isentress
St Vincent's Hospital, Sydney, Merck Sharp & Dohme LLC
Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)
10/13
10/13

Download Options